Immuneering (IMRX) | Stock Overview & Key Data
Immuneering Performance Comparison
Stock Range
Today's Range
Low: $5.17
High: $5.62
on September 5, 2025
52 Week Range
Low: $1.10
High: $6.35
on May 12, 2025
All-Time High: $33.99 on August 2, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$235.0M
EPS
-1.90
P/E Ratio (TTM)
-2.70
Forward P/E
-3.29
P/B Ratio
6.71
PEG Ratio
0.18
Div. Yield
N/A
ROE
-130.47%
Beta
0.430
Debt to Equity
13.83
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-68.37%
Return on Equity (TTM)
-130.47%
EBITDA
$-63.7M
Net Income (TTM)
$-62.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Immuneering IMRX | 234.99M Micro-cap | -4.17% | 54.34% | 168.78% | 267.33% | 149.32% | 366.95% | -37.88% | -68.68% |
| Vertex VRTX | 101.56B Large-cap | 1.30% | 5.64% | -10.75% | -19.43% | -2.38% | -15.36% | 35.61% | 53.56% |
| Regeneron REGN | 60.77B Large-cap | -1.26% | 0.61% | 18.70% | -16.56% | -19.83% | -49.33% | -20.84% | 5.26% |
| Third Harmonic Bio THRD | 242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.85% | -51.27% | -53.82% | -70.11% | -70.11% |
| Tonix TNXP | 241.91M Micro-cap | -10.43% | -44.36% | -30.90% | 142.15% | -15.48% | 76.93% | 76.93% | 76.93% |
| Invivyd IVVD | 238.69M Micro-cap | 17.53% | 58.33% | 22.58% | 7.55% | 137.50% | 40.74% | -75.22% | -94.54% |
Ownership & Short Interest
Insider Ownership
24.12%
Institutional Ownership
10.57%
Shares Short
2M
Short Ratio
3.83
Short % of Shares Outstanding
5.69%
Average 10-Day Volume
862K
Average 90-Day Volume
719K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is IMRX's 52-week high and low?
- In the last 52 weeks, Immuneering reached a high of $6.35 (on N/A) and a low of $1.10 (on May 12, 2025).
- What is the market cap and P/E ratio for IMRX?
- Curious about Immuneering's size and valuation? Its market capitalization stands at 234.99M. When it comes to valuation, the P/E ratio (trailing twelve months) is -2.70, and the forward P/E (looking ahead) is -3.29.
- Does IMRX pay dividends? If so, what's the yield?
- As for dividends, Immuneering isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Immuneering's main competitors or similar companies to consider before investing?
When looking at Immuneering, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.56B Healthcare Biotechnology -15.36% 35.61% Regeneron
REGN60.77B Healthcare Biotechnology -49.33% -20.84% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% Tonix
TNXP241.91M Healthcare Biotechnology 76.93% 76.93% Invivyd
IVVD238.69M Healthcare Biotechnology 40.74% -75.22% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Immuneering Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Immuneering's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -130.47%, the Debt to Equity ratio from the most recent quarter is 13.83, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for IMRX?
- Looking at Immuneering's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of IMRX stock is held by insiders and institutions?
- Wondering who owns Immuneering stock? Company insiders (like executives and directors) hold about 24.12% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 10.57%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.